Myriad Genetics第四季度调整后每股收益$0.03,与预期一致,销售额$2.106亿低于预期$2.116亿

财报速递2025-02-25
Myriad Genetics(NASDAQ:MYGN)报告季度每股收益为$0.03,符合分析师的一致预期。这比去年同期的每股收益$0.04下降了25%。公司报告季度销售额为$2.106亿,低于分析师一致预期的$2.116亿,差距为0.48%。但相比去年同期的销售额$1.966亿增长了7.12%。

以上内容来自Benzinga Earnings专栏,原文如下:

Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 percent. This is a 7.12 percent increase over sales of $196.60 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法